Christopher Walton

Christopher Walton

orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1997 in JACC
Verified
Journal Article
Closed access
JSJonathan W Swan
Jonathan W Swan
SAStefan D Anker
Stefan D Anker
CWChristopher Walton
Christopher Walton
IGIan F Godsland
Ian F Godsland
ACAndrew L Clark
Andrew L Clark
ACAndrew J.S Coats
Andrew J.S Coats

1 June 1998 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
FLFrancisco Leyva
Francisco Leyva
IGIan F. Godsland
Ian F. Godsland
MGMohammed Ghatei
Mohammed Ghatei
APAnthony J. Proudler
Anthony J. Proudler
SAStephen Aldis
Stephen Aldis
JSJohn C. Stevenson
John C. Stevenson
—In humans, production of the adipocyte-derived peptide leptin has been linked to adiposity, insulin, and insulin sensitivity. We therefore considered that alterations in plasma leptin concentrations could constitute an additional component of a metabolic syndrome of cardiovascular risk. To explore this hypothesis, we employed factor analysis, a multivariate statistical technique that allows reduction of large numbers of highly intercorrelated variables to composite, biologically meaningful factors. Seventy-four men [age, 48.4±1.3 years (mean±SEM); body mass index (BMI), 25.6±0.3 kg/m 2 ] who were free of coronary heart disease and diabetes underwent anthropometric measurements (subscapular-to-triceps [S:T] and subscapular-to-biceps [S:B] skinfold thickness ratios, measurement of fasting plasma leptin, and an intravenous glucose tolerance test (IVGTT) for assessment of insulin sensitivity. Plasma leptin concentrations were correlated with BMI ( r =0.57, P <0.001), S:T ( r =0.34, P =0.003), S:B ( r =0.37, P <0.001), systolic and diastolic blood pressures (both r =0.24, P =0.044), fasting triglycerides ( r =0.31, P =0.007), serum uric acid ( r =0.35, P =0.003), fasting glucose ( r =0.32, P =0.003) and insulin ( r =0.33, P =0.004), and IVGTT insulin ( r =0.63, P <0.001). A negative correlation was observed between leptin and insulin sensitivity ( r =−0.32, P =0.006). No significant correlations emerged between plasma leptin concentrations and age, high density lipoprotein cholesterol, or IVGTT glucose. In multivariate regression analyses, BMI (standardized coefficient [SC] =0.40, P =0.001), fasting insulin (SC=0.23, P =0.036), and IVGTT insulin (SC=0.51, P <0.001) emerged as independent predictors of plasma leptin concentrations ( R 2 =0.56, P <0.001). After adjustment for BMI, only IVGTT insulin emerged as a significant predictor of plasma leptin concentrations (SC=0.56, P <0.001, R 2 =0.45, P <0.001). Factor analysis of plasma leptin concentrations and the variables that are considered relevant to the insulin resistance syndrome revealed a clustering of plasma leptin concentrations with a factor dominated by insulin resistance and high IVGTT insulin, separate from a high IVGTT glucose/central obesity factor and a high triglyceride/low high density lipoprotein cholesterol factor. Together, these factors accounted for 55.9% of the total variance in the dataset. In conclusion, interindividual variations in plasma leptin concentrations are strongly related to the principal components of the insulin resistance syndrome. Further studies are needed to determine whether the insulin-leptin axis plays a coordinating role in this syndrome and whether plasma leptin concentrations could provide an additional measure of cardiovascular risk.

1 December 2009 in Journal of Breath Research
Verified
Journal Article
Closed access
CTClaire Turner
Claire Turner
CWChristopher Walton
Christopher Walton
SHShu Hoashi
Shu Hoashi
MEMark Evans
Mark Evans
Conventional wisdom is that breath acetone may be markedly elevated in type 1 diabetes, but that this only occurs during poor blood glucose control and/or intercurrent illness. In contrast, little is known about breath acetone at more representative everyday blood glucose levels in diabetes. We used selected ion flow tube mass spectrometry to monitor the breath of eight patients with type 1 diabetes mellitus during 'insulin clamp' studies in which insulin and glucose were infused into patients to lower blood glucose levels in steps from normal values into the low glucose (hypoglycaemic) range. The concentration of acetone in breath and the blood sugar concentration of the patients were monitored at each blood glucose concentration. The blood glucose level at the start of the study was typically about 6 mM L(-1), whereas the breath acetone concentration at this blood glucose level was unexpectedly variable, ranging from 1 part-per-million to 21 ppm, in contrast to what was previously believed, i.e. that type 1 diabetes mellitus is characterized by high acetone levels. In all eight patients, the breath acetone declined linearly with blood glucose concentration.

1 August 1993 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
CWChristopher Walton
Christopher Walton
IGI. F. Godsland
I. F. Godsland
APA. J. Proudler
A. J. Proudler
VWV. Wynn
V. Wynn
JSJ. C. Stevenson
J. C. Stevenson

1 July 1993 in Metabolism
Verified
Journal Article
Closed access
IGIan F. Godsland
Ian F. Godsland
KGKevin Gangar
Kevin Gangar
CWChristopher Walton
Christopher Walton
MCMichael P. Cust
Michael P. Cust
MWMalcolm I. Whitehead
Malcolm I. Whitehead
JSJohn C. Stevenson
John C. Stevenson

1 November 1995 in The American Journal of Medicine
Verified
Journal Article
Closed access
CWChristopher Walton
Christopher Walton
BLBelinda Lees
Belinda Lees
DCDavid Crook
David Crook
MWMelek Worthington
Melek Worthington
IGIan F. Godsland
Ian F. Godsland
JSJohn C. Stevenson
John C. Stevenson